Roberto Iacone, Roche, Discusses the Use of Stem Cells in Diabetic Cardiomyopathy Research

Dr. Iacone describes the incorporation of iPSC-derived iCell® and MyCell® Cardiomyocytes into their research program in diabetic cardiomyopathy associated with Type II diabetes and how these cells may enable development of personalized medicine.